Israel: A new study published in JAMA Network Open highlights a key safety insight for patients with type 2 diabetes taking ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in patients ...

Smartphone-based home screening significantly boosts chronic kidney disease (CKD) diagnosis and follow-up care, enhancing ...

A study published in JAMA Surgery involving nearly 500,000 surgeries among U.S. veterans found that patients taking SGLT2 ...

In the case of diabetic women, the vaginal microbiome is significantly lower and changed compared to healthy women, requiring ...

Originally designed as glucose-lowering medications, SGLT2 inhibitors provide benefits across the cardio-renal-metabolic ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a newer type of medication used to help people with diabetes manage ...

After the SGLT2 inhibitors were shown to benefit patients with type 2 diabetes, reducing cardiovascular events, including hospitalization for heart failure, the next natural research question, ...

Despite incomplete evidence, longevity enthusiasts are experimenting with SGLT2 inhibitors in their quest to live healthier for longer.